{"classes":[{"categories":[{"measurements":[{"comment":"Median and lower limit of CI was not reached due to low number of participants with events.","groupId":"OG000","lowerLimit":"34.99","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Overall Survival is the time in months from start of study treatment to date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m\\^2, tablets, orally, on Days 1 to 4 and prednisone 60 mg/m\\^2, tablets, orally, on Days 1 to 4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 49 maintenance cycles; overall up to 61 cycles \\[58 months\\]).","id":"OG000","title":"Arm B: Ixazomib 4.0 mg (RP2D)"}],"paramType":"MEDIAN","populationDescription":"The safety population consisted of participants who received at least 1 dose of any study drug.","reportingStatus":"POSTED","timeFrame":"From date of enrollment to date of death, approximately 5.5 years (Approximate median follow-up: 43.6 months)","title":"Overall Survival (Phase 2)","type":"SECONDARY","unitOfMeasure":"months"}